The most common prescribed drugs for MASLD are antidiabetic, including insulin sensitizers, peroxisome proliferator-activated receptor (PPAR) agonists, glucagon-like peptide 1 receptor agonists (GLP-1 RA), glucagon agonists, lipogenesis inhibitors, and more recently, thyromimetics [18]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.